Mobile

Study in patients with moderate to severe plaque psoriasis to assess efficacy of secukinumab compared to Fumaderm®

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-005258-20

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate the superiority of secukinumab compared to Fumaderm® in subjects with moderate to severe plaque psoriasis based on the proportion of PASI 75 responders at week 24.

Critère d'inclusion

  • chronic moderate to severe plaque type psoriasis

Liens